Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Relugolix - Myovant/Takeda

Drug Profile

Relugolix - Myovant/Takeda

Alternative Names: Relumina; RVT 601; TAK-385

Latest Information Update: 21 Aug 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Takeda
  • Developer ASKA Pharmaceutical; Myovant Sciences; Takeda; Takeda Oncology
  • Class Analgesics; Antineoplastics; Fluorobenzenes; Ketones; Pyridazines; Pyrimidines; Small molecules; Thiophenes; Urea compounds
  • Mechanism of Action LHRH receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Uterine leiomyoma
  • Phase III Endometriosis; Pain; Prostate cancer
  • No development reported Solid tumours

Most Recent Events

  • 20 Aug 2019 Myovant completes enrolment in its phase III Spirit 2 trial for endometriosis associated Pain (Monotherapy) in USA, United Kingdom, Sweden, New Zealand, Italy, Georgia, Australia, Canada, Czech Republic, Poland, Brazil, Chile, Romania (PO)
  • 06 Aug 2019 Myovant Sciences plans to submit Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Uterine leiomyoma (Combination therapy) (PO) in the first quarter of 2020
  • 23 Jul 2019 Efficacy and adverse events data from the phase III LIBERTY 2 trial in Uterine leiomyoma released by Myovant Sciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top